Randomized Phase II, 2-arm Study of Immunomodulation With Atezolizumab Concomitant With High Dose Radiation (SBRT) Versus SBRT Alone in Patients With Oligometastatic Sarcomas
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms Stereosarc
- 06 Nov 2019 Planned initiation date changed from 1 Sep 2019 to 15 Jan 2020.
- 15 Mar 2019 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2019.
- 12 Jun 2018 New trial record